En studie av TNB-486 hos patienter med återfall eller refraktärt B-cells non-Hodgkin lymfom
En multicenter, fas 1, öppen studie, dosökning och expansionsstudie av TNB-486, en bispecifik antikropp riktad mot CD19 hos patienter med återfall eller refraktärt B-cells non-Hodgkin-lymfom
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This dose escalation and optimization study, is evaluating the safety, tolerability, PK, PD and clinical activity of AZD0486 monotherapy.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Heidelberg, Australien, 3084
- Research Site
-
Hobart, Australien, 7000
- Research Site
-
Melbourne, Australien, 3004
- Research Site
-
-
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40207
- Research Site
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28204
- Research Site
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15237
- Research Site
-
-
Texas
-
Austin, Texas, Förenta staterna, 78704
- Research Site
-
Houston, Texas, Förenta staterna, 77030
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Research Site
-
-
-
-
-
Chūōku, Japan, 104-0045
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Nagoya, Japan, 460-0001
- Research Site
-
Yamagata, Japan, 990-9585
- Research Site
-
-
-
-
-
Seoul, Sydkorea, 03080
- Research Site
-
Seoul, Sydkorea, 05505
- Research Site
-
Seoul, Sydkorea, 06351
- Research Site
-
Seoul, Sydkorea, 06591
- Research Site
-
Seoul, Sydkorea, 120-752
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833401
- Research Site
-
Kweishan, Taiwan, 333
- Research Site
-
Tainan, Taiwan, 704
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Biopsy proven B-NHL, including DLBCL, HGBL, or FL.
- Relapsed/refractory cohorts:
In order to be eligible subjects must have received at least 2 prior lines of therapy and not be candidates for treatment regimens known to provide clinical benefit in B-NHL. CAR T-naive subjects are allowed if they have declined, are considered ineligible for, or do not have timely access to CAR T cell therapies.
- 1L FL cohorts: Subject has biopsy-proven FL Grade 1-3a per WHO 2016 classification, Stage II-IV, FL International Prognostic Index 2-5 that has not been treated with prior systemic lymphoma-directed therapy and requires initiation of treatment based on GELF criteria. Radiation to localized disease prior to study entry is allowed if >14 days from first dose.
- All Cohorts:
Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
- Subject must have adequate liver, bone marrow and kidney function (eGFR ≥ 50 mL/min).
- Subject must have locally confirmed CD19 positivity (must be documented after time of progression from last CD19-targeted therapy, if received)
- Subject must have at least 1 measurable disease site
- Subject must have ANC >/= 1000/mm3, platelets >/= 50,000 mm3, hemoglobin >/= 8.0 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening
- Subject must have a total bilirubin <1.5x ULN, AST/ALT < 3xULN
Exclusion Criteria:
- Subject has been diagnosed with or treated for another malignancy whose natural history or treatment may interfere with the safety or efficacy assessment of the investigational regimen.
- Subject has active central nervous system (CNS) involvement by their B-NHL. --Subjects may be eligible with a distant history of CNS involvement that has been adequately treated with no evidence of recurrence within last 6 months from screening.
- Subject has a history of leukemic presentation of their B-NHL (>5,000 circulating lymphoma cells/uL in the peripheral blood).
- Subject has history or presence of clinically significant CNS pathology
- Subject has CNS involvement from active or history of autoimmune disease.
- Subject received CD19 CAR T therapy within 3 months prior to first dose.
- Subject experienced Grade ≥ 3 cytokine release syndrome (CRS) following prior T-cell engager (TCE) or CAR T-cell therapy.
- Subject experienced Grade ≥ 2 neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) following prior TCE or CAR T-cell therapy.
- Subject has received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study drug treatment or has received an SCT and requires ongoing immunosuppressive therapy.
- Subjects with human immunodeficiency virus (HIV) infection, or subjects with chronic or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Subjects with chronic HBV may be enrolled if the HBV viral load is undetectable on suppressive therapy, or if the subject has a documented cure. Subjects with HCV who have a documented cure may be enrolled.
- Subject has a history of major cardiac abnormalities.
- If female, subject must not be pregnant or breastfeeding.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: AZD0486 Monotherapy Dose Escalation in Subjects with B-NHL
AZD0486 monotherapy will be administered intravenously on day 1 and 15 of 28 day cycles for a maximum of 2 years or until discontinuation criteria are met. Depending on cohort, subjects may receive priming or step-up dosing administered weekly during cycle 1 before reaching the target dose. Additional cohorts may be opened where subjects receive weekly dosing during Cycles 1-2. While on study, subjects will be monitored for safety and efficacy with periodic disease assessment with PET/CT. If subject achieves two consecutive CRs after completing C6, then they may be eligible for monthly dosing |
AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of subjects with Dose-limiting toxicities (DLT)
Tidsram: 28 days
|
A DLT is defined as a TEAE that is not unequivocally due to the subject's underlying malignancy or other extraneous cause. DLT evaluable subjects are defined as those subjects who receive either the target dose of AZD0486 or priming dose(s) in any step-up dose schedule and are assessed for toxicities for the 28-day evaluation period. The NCI-CTCAE version 5.0 will be used (except for CRS and NT). A DLT will be evaluated as Non-hematologic, Hematologic, Cytokine Release Syndrome (CRS), or neurotoxicity. |
28 days
|
|
Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs)
Tidsram: From screening until 90 Days after end of treatment
|
The incidence, timing, seriousness, and relationship to study treatment of adverse events will be evaluated. |
From screening until 90 Days after end of treatment
|
|
Maximum Observed Serum Concentration of AZD0486 (Cmax)
Tidsram: 4 Weeks
|
The maximum observed serum concentration on a concentration time curve. |
4 Weeks
|
|
Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast)
Tidsram: 4 Weeks
|
Area under the serum concentration-time curve from time zero to time of last measurable concentration. |
4 Weeks
|
|
Apparent terminal half-life (t1/2) of AZD0486
Tidsram: From screening until 90 Days after end of treatment
|
Terminal half-life (t1/2,) will be determined after infusion in Cycle 1 using non-compartmental methods. |
From screening until 90 Days after end of treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Anti-Lymphoma Activity by Objective Response Rate (ORR)
Tidsram: 48 months
|
Objective response rate is defined as the proportion of subjects with a confirmed partial or complete response to treatment |
48 months
|
|
Anti-Lymphoma Activity by Progression-Free Survival (PFS)
Tidsram: 48 months
|
Progression-free survival time is defined as the time from the first dose of AZD0486 to progression or death, whichever occurs first |
48 months
|
|
Anti-Lymphoma Activity by Duration of Objective Response (DOR)
Tidsram: 48 months
|
The duration of objective response for a subject is defined as the time from the initial objective response to disease progression or death, whichever occurs first |
48 months
|
|
Anti-Lymphoma Activity by Clinical Benefit Rate
Tidsram: 48 months
|
Clinical benefit rate is defined as the proportion of subjects with a confirmed complete response, partial response or minor response, or stable disease for at least 24 weeks after responding to treatment |
48 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: David Sermer, MD, AstraZeneca
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D7400C00006
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting
Tidsram för IPD-delning
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria:
Kriterier för IPD Sharing Access
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .